All Episodes
The Readout Loud — 406 episodes
401: Makary’s departure and Cassidy’s tenuous Senate seat
400: Seaport's IPO adventure, obesity pill battles, and Makary's troubles
399: Hair-raising trial results, and Servier’s M&A wishlist
398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts
397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment
396: A new trick for old science, and biotech VCs' scrambled playbook
395: Biotech investors' plea to Trump, and a busy M&A week
394: Eli Lilly's deal man, Allogene's off-the-shelf CAR-T, and Merck's Terns buy
393: A conversation with the 'godfather' of biotech
392: Epstein's pal attempts a biotech comeback, and Prasad exits the FDA
391: Breaching the IBD efficacy ceiling, and sham surgeries
390: FDA turmoil, election intrigue, AI, and more
389: Hims' Super Bowl fallout, and the FDA reverses course
388: The FDA's refusal to review Moderna's mRNA flu vaccine
387: Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s
From Drug Story: Lipitor and Heart Disease
386: The high stakes for Huntington's patients
385: A measles outbreak and hospitals' financial troubles
384: Live from the JP Morgan conference, a sit-down with Novo Nordisk's CEO and VC Bob Nelsen
383: JPM to bring more deals and happy CEOs
382: Biotech's year in review
381: The future of American science and a dispatch from ASH
380: A new top drug regulator and the future of psychedelics
379: How Mark Cuban plans to ‘f— up’ health care
378: Merck's heart disease win and the FDA's new drug regulator
377: Melodrama at the FDA and the Pfizer-Novo bidding war
376: BridgeBio’s great week and Moderna’s unraveling
375: Startups push the FDA and biotech booms in North Carolina
374: Veteran biotech executive Clive Meanwell on drug pricing and the obesity market
373: Party in biotech land and AstraZeneca’s miscalculation
372: A pharma C-suite shakeup and Trump's deal with Pfizer
371: A gene therapy success in Huntington's and Trump's autism announcement
370: Pharma sours on the U.K., plus biotech M&A's quiet roll
369: Trump, Chinese biotech, and an industry career reshaped by illness
368: New stakes in the vaccine dispute and a boost for biotech
367: The ouster of CDC's director, biotech venture firm rankings
366: Viking’s obesity flop, ‘pharma to table’ drug sales
365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended
364: Closing a zombie biotech, and Lilly's disappointing obesity readout
363: What Vinay Prasad’s ouster means for biotech and the FDA
362: A mother’s perspective on Sarepta’s gene therapy halt
361: Inside an FDA drug rejection, and layoffs at Sarepta
360: NIH grant cuts, FDA transparency questions and biotech M&A
359: Vaccine policy frays, CDC nominee in the hot seat, & obesity drug side effects
358: FDA's gene therapy turmoil, and an alternative model for funding research
357: The upheaval of CDC's vaccine panel, and drug pricing confusion
356: An AI experiment at the FDA & Novo trailing in the obesity drug race
355: Moderna’s vaccine hit, the MAHA report, and an ASCO preview
354: Uncertainty in CRISPR world and the start of more M&A
353: Trump's drug-pricing plan and a potential Theranos 2.0
352: A firebrand takes oversight of vaccines, gene therapies
351: It's gonna be May (in biotech)
350: Pharma tariffs, and a 'sunshine day' for biotech stocks
349: BIO's John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding
348: Cuts, ousters and drama at the FDA
347: More HHS upheaval, 23andMe's bankruptcy, and AI for cancer survival
346: Zealand's obesity strategy and Immunovant's curious development plan
345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies
344: Trump's FDA commissioner nominee takes the hot seat
343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs
342: FDA cuts, zombie biotechs, and too much weight loss?
341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers
340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug
339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad
338: Chinese biotechs, a WHO departure, and post-JPM thoughts
337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss
336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study
335: A deep dive on Makary, Vertex's pain data, & 2025 predictions
334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children
333: An H5N1 bird flu update and talent scarcity in the radiopharma field
332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?
331: AbbVie’s stumble, Amgen’s tumble and more election fallout
330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks
329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story
328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions
327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights
326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI
325: Biden's health care AI czar, a new obesity company, and its dealmaking CEO
From Tradeoffs: Race to the Bottom
324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug
323: Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates
322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids
321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target
320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy
From "Say More": What Happens When AI Decides Your Medical Coverage
319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides
318: Drug pricing drops & psychedelics under fire
317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision
316: The long journey to make malaria vaccines, and Sarepta's ties with patient advocates
315: UnitedHealth's doctor empire, an FDA departure, and Viking's obesity moves
314: JD Vance's biotech ties, Cassava resignations, and insulin shortages
313: Biotech layoffs, founder-focused VC, & a big pharma exit
312: Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate
311: Fauci's memoir, Alnylam's tenuous trial, and a mid-year review
310: Duchenne gene therapy setback, Alzheimer's drug endorsement & why a STAT reporter buys weed (for journalism)
309: Psychedelics at the FDA, ASCO recap, & MorphoSys update
308: An ASCO preview & another Duchenne trial failure
307: More tumult at BIO & coercive care for sickle cell patients
306: Live! From the STAT Breakthrough Summit West
305: Everything you need to know about H5N1 bird flu
304: Controversial brain tissue research, obesity drug sales and Novartis’ M&A drama
303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc
302: Vertex's big deal, biotech's red numbers, & an industry history lesson
301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise
300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
299: Live! From the STAT Breakthrough Summit East
298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
297: VC turmoil, GLP-1 competition, & the war on recovery
296: Legal insider trading, booming biotech stocks, & the next GLP-1
295: Humira’s legacy, CEO symbolism, and genomic surgery
294: Pharma goes to Washington, Alnylam's future, & Gilead's dealmaking
293: AI in medicine, detangling hype, and Icelandic DNA
292: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon
291: The plight of the VC, Gilead's latest setback, & more M&A
290: Biotech layoffs, slumping stocks, and a 2024 preview
289: Live! From #JPM24
287: 2023 in review, CEO report cards, and a look at the year ahead
286: FTC v. biotech, Pfizer's kitchen sink, & Vertex's future
285: CRISPR history, biotech struggles, & a big week for deals
284: AbbVie’s big deal, CAR-T’s risks, & getting a biotech job
283: A CRISPR milestone, algorithms amok, & biotech mixology
From Tradeoffs: Can the U.S. put an end to surprise ambulance bills?
282: Lilly’s obesity drug, the power of radiation, & a biotech implosion
281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO
280: ESMO highlights, Roivant's big deal, & biotech VC on the rise
279: Live from the 2023 STAT Summit
278: Merger Mondays, Ozempic panic, & CRISPR'd pigs
277: Is the Nobel committee evolving? Plus, preventing public health's wiliest virus
276: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech's slump
275: A thorny ALS debate at the FDA, and the promise of artificial wombs
274: Covid’s latest surge, Alnylam at the FDA, & the end of an era
273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter
272: Vivek's star turn, leaky drug data, & biotech as family business
271: Racing for gene therapy, a pioneering approval, & startups in the lurch
270: Your guide to Wegovy’s blockbuster heart study
269: Biotech layoffs, eye drug drama, & gene therapy milestones
268: Biogen's sticky situation, Wegovy's risks, & biotech insider trading
267: BridgeBio's big week, Lilly's Alzheimer's data, & succession at Stanford
266: Wegovy in the brain, pivotal Alzheimer's data, & pulling Threads
265: Novavax's CEO promises a turnaround & how Lilly roiled the obesity market
264: Messy PBM conflicts, debatable vaccines, & the future of flu season
263: Biogen's messy board, Laronde's data problem, & the downside of a boom
262: Merck v. USA, the best of ASCO, and Leqembi at the FDA
261: Fake medical devices, real cancer drugs, & curious Ozempic effects
260: ChatGPT in medicine, a boom in weight loss pills, & Sarepta at the FDA
259: The FTC v. Amgen, Sarepta's future, & Galapagos' turnaround
258: Pharma vs. PBMs, Sarepta at the FDA, & a bold idea gone awry
257: Lilly's Alzheimer's success, a milestone FDA approval, & Moderna's shrinking business
256: Explaining the E.U.'s pharma overhaul, Lilly's booming business, & a long-awaited drug approval
255: Sarepta's pivotal moment, biotech's big week, & the future of Covid boosters
254: The legal battle over abortion, an FDA 'bully pulpit' and Moderna's future
253: Illumina’s boardroom intrigue, the next big Alzheimer’s readout, & J&J’s creative lawyers
252: Biotech's monkey shortage, the broken generics market, & conference cancel culture
251: Bancel v. Bernie, Sarepta's FDA runaround, & Regeneron's ever-growing blockbuster
250: SVB's long biotech shadow, pushy AI algorithms, & Icahn v. Illumina
249: Robert Califf on how drugs get approved, plus the nascent revolution in obesity
248: The next CRISPR fight, cheaper insulin, & an FDA shuffle
247: Vertex vs. insurers, Moderna's future, & biotech's long winter
246: Vas Narasimhan on the future of pharma, plus Moderna’s promise & a biotech presidential bid
245: The return of bird flu and the effects of pandemic fatigue
244: Pharma blockbusters, pandemic policy, & legal chicanery
243: George Scangos' retirement, annual Covid vaccines, an Alzheimer's drug rejection
242: How blockbusters get made, new vaccines for RSV, and mRNA's Q score
241: #JPM23 in review, the year ahead, & the merits of Miami
240: #JPM23, the future of Alzheimer's, & rising Covid variants
239: 2022 in review, CEO indictments, & the year ahead
238: Leaky health data, ASH22, & what it takes to get booed by your peers
237: The 'electric vehicles' of pharma, Illumina's boondoggle, & a Theranos sentencing
236: Wither PhRMA, Alzheimer's treatment data revealed, and the first fecal microbiome drug approval
235: LIVE from the STAT Summit
234: Biogen's new CEO, how the midterms affect science, & a biotech bankruptcy
233: How the biotech revolution could come apart at the seams
232: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms
231: BU's Covid tinkering, FDA on trial, & why it's hard to take drugs off the market
230: BIO's messy transition, mRNA's future, & Biogen's next CEO
229: Nobels for science, biotech dealmaking, & a friendly FTC
228: A surprise success in Alzheimer's and how FDA history seeded modern controversy
227: Biden's Covid declaration, twilight of the SPAC, & genome editing 2.0
226: Pharma's telehealth gold mine, the return of the biotech IPO, & a merger deferred
225: Illumina's $8 billion limbo, a new treatment for ALS, & Emirati biotech funding
224: The anti-aging research boom, the Godfather of biotech, & the future of Biogen
223: Fauci's non-retirement, grading biotech VCs, & a bellwether IPO
222: Private equity in autism care, a watershed FDA approval, & the future of ALS treatment
221: Big egos in Big Science, the return of Merger Monday, & the fallout over drug pricing
220: The last-minute push for drug pricing reform, Alnylam's success, and Sarepta's gamble
219: Helen Branswell on monkeypox, plus: an FDA controversy and fake Alzheimer's data
218: Well-paid CEOs, behind the scenes at Moderna, & Biogen's CEO search
217: CRISPR for the heart, biotech's recovery, & what it means to be a 'hot girl'
216: VC malaise, FDA confusion, & yet another Alzheimer's debate
215: Medical privacy post-Roe, fixing clinical trials, & the next Covid vaccines
214: Juul's doomsday, Merck's buyout plans, & the next Theranos verdict
213: How the Fed affects biotech, Paul Offit on vaccines for kids, & another Alzheimer's setback
212: Applause-worthy cancer data, the long wait for Novavax, & the next FDA controversy
211: Biotech's catch-22, a $100 genome, & dealing with monkeypox
210: Covid vaccines for the youngest kids, ASCO preview, & a biotech CEO’s arrest on murder charges
Episode 209: Mysterious infections, dwindling Covid funds, & Shkreli out of prison
Episode 208: A CEO's arrest, Pfizer's big deal, & Covid on the rise
Episode 207: Succession at Biogen, surprises at Vertex, & a potential superspreader dinner
Episode 206: How cancer-killing cell therapies work, biotech's endless downturn, & an FDA conundrum
Episode 205: An ominous biotech deal, vaccines for kids, & 'breakthrough' devices
Episode 204: Leana Wen on the pandemic's new normal and whether Twitter is real life
Episode 203: What's next for Roche, a debate over second boosters, & Vertex's recent success
Introducing: Color Code
Episode 202: Helen Branswell on the pandemic, plus the next FDA debate & the perks of being a CEO
Episode 201: Doing biotech in Ukraine, drug pricing déjà vu, & Covid surges overseas
Episode 200: Gilead's growing pains, Covid's origins, & Theranos as prestige TV
Episode 199: Biden's plans for Covid pills, the latest vaccine data, & fighting about CRISPR
Episode 198: Medical racism, new Covid vaccines, & the resilience of Regeneron
Episode 197: Robert Califf's FDA return, the future of CRISPR, & another vaccine delay
Episode 196: Eric Lander's resignation, FDA's about-face, & Pfizer's lucrative pandemic
Episode 195: Califf's sudden jeopardy, the quest for a PCSK9 pill, & Covid vaccines for kids
Episode 194: Janet Woodcock on Covid antibodies, vaccines for kids, and responding to Omicron
Episode 193: Jared Holz on Biotech's red tape, plus the latest billionaire science project
Episode 192: Michael Gilman on the future of RNA drugs, plus #JPM22 in review and more Biogen news
Episode 191: Craig Spencer on the Omicron surge + biotech in 2022, & the Elizabeth Holmes verdict
Episode 190: Covid in 2022, J.P. Morgan bows to pressure, & the year in review
Episode 189: Biogen, Biogen, Biogen, with a dash of Omicron
Episode 188: Carlos del Rio on Covid antivirals, an FDA conundrum, & the rise of Omicron
Episode 187: Biogen’s scientific succession & Michael Osterholm on pandemic Thanksgiving
Episode 186: Rebecca Robbins on Moderna v. NIH, plus psilocybin as a medicine
Episode 185: John Maraganore on his next act, plus Moderna's setback & the drug pricing reform saga
Episode 184: Vaccines for kids, inside Operation Warp Speed, & a big biotech resignation
Episode 183: Greg Zuckerman on the vaccine race, plus Biogen's troubled launch
Episode 182: The FDA star search, more booster debates, & the future of mRNA
Episode 181: Brent Hodge on filming Shkreli, the next NIH director, and a looming FDA deadline
Episode 180: Health equity 'tourism,' an $11B biopharma acquisition, & a bony Covid protest
Episode 179: Scott Gottlieb on the next pandemic, another Covid winter, & Aduhelm's slow rollout
Episode 178: Futuristic prosthetics, a treatment for ALS, & intrigue at the Holmes trial
Episode 177: Bijan Salehizadeh on Covid tests, plus Verily's moment of truth
Episode 176: Elizabeth Holmes on trial, FDA in disarray, & the quest for Covid antivirals
Episode 175: Dorit Reiss on vaccine mandates, plus biotech's messy summer
Episode 174: Biotech's trust issues, overwhelmed health workers, & the nuances of insider trading
Episode 173: Biden's drug pricing plan, Wall Street's Alzheimer's fixation, & daily 5 a.m. alarms
Episode 172: The mRNA gold rush, Delta's alarming rise, & the next treatment for Alzheimer's
Episode 171: The quest for a Covid pill, a microbiome gut-check, & CRISPR on the big screen
Episode 170: Céline Gounder on breakthrough infections, plus the power of lobbying
Episode 169: Dan Diamond on covering Biden, plus the FDA's future, & the latest Aduhelm twist
Episode 168: Aduhelm's latest twist, & how Covid variants are shaping the summer
Episode 167: George Yancopoulos on biotech in 2021, plus a CRISPR milestone, Biogen's FDA saga,
Episode 166: FDA inner workings, GSK's foggy future, & the alarming rise in colorectal cancer
Episode 165: Paul Offit on the Covid vaccine booster debate, & Robyn Karnauskas' call of the decade
Episode 164: Every angle on the FDA's polarizing approval of Biogen's Alzheimer's drug
Episode 163: Marilynn Marchione on covering the CRISPR babies scandal
Episode 162: Scott Gottlieb on Covid and grilling, plus how Zolgensma has changed SMA
Episode 161: Biotech meme stocks, the lessons of Spanish Flu, & becoming a pandemic celebrity
Episode 160: Global Covid-19 failures, a sluggish CDC, and a boisterous STAT Health Tech Summit
Episode 159: Thomas Bollyky on patent waivers, plus vaccine riches, & a gene therapy for aging
Episode 158: Angela Rasmussen on Russia's vaccine controversy, plus Biden's drug pricing punt
Episode 157: Mercedes Carnethon on outdoor masking, FDA in limbo, & gene therapy's uncertain upside
Episode 156: J&J's vaccine pause, talking about remote risks, & why no new drugs for Covid-19
Episode 155: AstraZeneca's vaccine woes, compassionate use, & giving out Covid vaccines
Episode 154: Eleanor Fox on Illumina’s FTC headache, plus Talkspace’s experiment
Episode 153: AstraZeneca and the very good, then quite bad, then deeply confusing week
Episode 152: Alison Buttenheim on Europe's vaccine scare, Lilly's Alzheimer's data, & a PR plea
Episode 151: Natasha Loder on Covid vaccines, the demise of Watson Health, and a 'synbio' explainer
Episode 150: Ashish Jha on Covid-19 optimism, plus pharma cooperation, & the next pandemic phase
Episode 149: Nancy Goodman on Covid vaccines for kids, & Greg Zuckerman on Novavax's remarkable rise
Episode 148: Akshay Sharma on gene therapy's setback, biotech's brashest VCs, & the FDA's future
Episode 147: David Fajgenbaum on Covid-19 drugs, the state of the pandemic, & meme biotech stocks
Episode 146: Paul Offit on vaccine data, 23andMe is going public, & Merck's CEO is retiring
Episode 145: Kevin Davies on the CRISPR boom, & Megan Ranney on scientific misinformation
Episode 144: Remembering STAT's Sharon Begley
Episode 143: #JPM21: Déjà vu in Alzheimer's research, and OWS's legacy
Episode 142: Bob Nelsen on the pandemic's next phase, plus Biden's biopharma plans & a CES preview
Episode 141: Moderna's vaccine milestone, Warp Speed's hurdles, and biotech in 2021
Episode 140: Pfizer's Covid-19 vaccine — the debate, details, and distribution
Episode 139: Angela Rasmussen on AstraZeneca's confusing data, & Adam Koppel on biotech in 2021
Episode 138: The latest Covid-19 vaccine, Biden's pandemic plans, and Bill Gates unfiltered
Episode 137: Natalie Dean on Pfizer's Covid-19 vaccine, plus the FDA's Alzheimer's quandary
Bracing for a pandemic winter, Biogen's fortune at the FDA, and remembering a remarkable 12-year-old
Episode 135: Pfizer's Covid-19 mystery, Ashish Jha on pandemic response, & STAT turns 5
Episode 134: Erik Gordon on SPACs, plus Covid-19 vaccines, & Biogen's case in Alzheimer's
Episode 133: A week of pauses, pharma’s statehouse spending, & how HBCUs approach Covid-19 trials
Episode 132: How Trump's case of Covid-19 affects biotech, medicine, and the FDA with George Scangos
Episode 131: Saad Omer on Covid-19 vaccine trials, & Ethan Weiss on intermittent fasting
Episode 130: A road map for Covid-19, the gold rush in health tech, & D.C.'s pandemic unrest
Episode 129: Heidi Tworek on pandemic PR, plus the CDC's credibility crisis & a lightning round
Episode 128: AstraZeneca’s Covid-19 vaccine, coronavirus politics, & STAT’s Health Tech Summit
Episode 127: Eric Topol on Stephen Hahn, plus Covid-19 vaccine timelines, & the 2000th First Opinion
Episode 126: The FDA's chaotic week, Trump's effect on science, and Musk's big reveal
Episode 125: Shocking FDA rejections, a longevity science setback & Derek Lowe on Covid-19 vaccines
Episode 124: Pharma's lobbying dollars, Alnylam's future, and diversity in Covid-19 studies
Episode 123: Steven Salzberg's Twitter debate, a health tech mega-deal & Covid-19 vaccine prices
Episode 122: Gary Washburn on the NBA bubble, plus a DIY coronavirus vaccine, & behind VC numbers
Episode 121: Kate Bingham on vaccine data, Meg Tirrell on covering Covid-19, & a DNA detective story
Episode 120: Moderna's vaccine data, saving the U.S. pandemic response & systemic racism in medicine
Episode 119: Trump's FDA pressure, a microcosm of the pandemic, and squabbling over a vaccine
Episode 118: Remdesivir’s controversial cost, early vaccine promise, and AI at the end of life
Episode 117: Covid-19’s U.S. surge, GSK’s mystery whistleblower, and cancer care under coronavirus
Episode 116: Ezekiel Emanuel on vaccine politics & Tshaka Cunningham on diversifying genetic testing
Episode 115: The Chan-Zuck uprising, a virtual BIO, and the struggle to treat Covid-19
Episode 114: The killing of George Floyd, the drug industry's response, and what comes next
Episode 113: Life after a coronavirus vaccine, virtual ASCO, and remembering Larry Kramer
Episode 112: Moderna's scant coronavirus data and the plight of the day trader
Episode 111: Covid-19 in the White House, a Parkinson’s experiment & public health lessons from porn
Episode 110: Pandemic projections, Gilead's pricing dilemma & fighting Covid-19 in New York
Episode 109: Scott Gottlieb on Covid-19 treatments, reopening America, and going on TV every day
Episode 108: A vaccine official is ousted, how to use ventilators, & the fate of the JPM conference
Episode 107: Covid-19 disrupts D.C., how not to be boring on Zoom, and the trial of Elizabeth Holmes
Episode 106: Privacy in a pandemic, biopharma's big opportunity, and Shkreli's plea for a break
Episode 105: Pandemic exit strategies, how the outbreak affects patients, and Ken Burns takes on DNA
Episode 104: Fauci's star turn, the latest on coronavirus, and an under-the-radar Alzheimer's drug
Episode 103: Trump's coronavirus pivot, life inside the ICU & drug development in a pandemic
Episode 102: Voices from the coronavirus pandemic, in Italy, New York, and the high seas
Episode 101: Pharma’s response to coronavirus, Google's appetite for health data, & biotech in China
Episode 100: Wall Street's coronavirus freakout, clinical trial difficulties, and a look back
Episode 99: Genetic medicine w/ Ethan Weiss, drug industry infighting, & a microbiome review
Episode 98: Les Funtleyder on biotech investing; the Zolgensma lottery & billionaire philanthropy
Episode 97: Fake outbreak news, treating coronavirus, and biotech's Mount Rushmore
Episode 96: A chemist breaks bad, the latest on the coronavirus, and pharma’s slow Bern
Episode 95: The latest on the China virus, Sarepta's ongoing FDA saga, and biotech at Davos
Episode 94: EQRx's Alexis Borisy, Stephen Buck on his website for cancer patients, and a JPM recap
Episode 93: Josiah Zayner on getting canceled, good news in cancer, an Ebola vaccine saga
Episode 92: The decade in breakthroughs, the year in bad CEOs, and the viruses that cure disease
Episode 91: CAR-T's future, an alarming cancer trend & Chris Garabedian on Sarepta's FDA legacy
Episode 90: Biogen's big reveal, hot takes on Alzheimer's, & the science of one-eyed sheep
Episode 89: Warren's awkward home front, a dwarfism drug, and the sound of STAT Summit
Episode 88: Dr. David Sable on an alarming genetic test & Jorge Conde on the perils of bio-Twitter
Episode 87: Derek Lowe on China's new Alzheimer's drug, blockbuster fish oil, & STAT's birthday
Episode 86: Drugs that don't work, wearables in the desert, & excess 'innovation'
Episode 85: Every angle on Biogen's shocking Alzheimer's news
Episode 84: CRISPR with Netflix filmmakers, Pharma's future in China & where VC dollars come from
Episode 83: How biotech VC works w/ health care journalist Maggie Fox, Vioxx and synthetic biology
Episode 82: Drug shortages with Dr. Ben Davies, congressional paralysis & biotech's foul mood
Episode 81: Vaping upheaval, DNA test dynamics, & the future of genome editing
Episode 80: Unicorn growth spurts, Amgen's future, & mice on Twitter
Episode 79: Pelosi's drug pricing plan, Moderna's mRNA drug factories, and a DIY disease cure
Episode 78: Pharma existentialism, mainstreaming cyborgs, & FDA palace intrigue
Episode 77: Purdue, J&J, and a week of big opioid crisis news
Episode 76: Sarepta keeps a secret, an online army mobilizes, & China embraces biotech
Episode 75: The serious side of spit kits, how BiTEs leave a mark, & Sarepta's sluggish study
Episode 74: Novartis and the no good, very bad week
Episode 73: Canadian pills, corporate jets, & racists with spit kits
Episode 72: Vertex's regime change, the return of Ebola, & the rise of digital health
Episode 71: Elon Musk's monkey cyborg, Gilead's shifting future, & an app for anxiety
Episode 70: A whirlwind week in Washington, Sean Parker's mansion, & remembering a voice in biotech
Episode 69: The future of AbbVieGan, the dogma of amyloid, & some questionable biotech marketing
Episode 68: A controversial desire drug, courtroom genealogy, & the quest for longer life
Episode 67: Biohacking meets bureaucracy, and the latest twist in CRISPR world
Episode 66: The future of cancer treatment, blockbusters interrupted, & an infamous biotech party
Episode 65: A special episode from the halls of the ASCO meeting
Episode 64: Feuding professors, failing businesses, and journalism 101
Episode 63: Your ASCO preview, genetic whiplash, and a journalist's experience with cancer
Episode 62: Drug pricing partisanship, tech's march into health care, and Tinder for clinical trials
Episode 61: Pharma felonies, cardiac CRISPR, and a strange day at the FDA
Episode 60: Boardroom drama, whiskey-fueled science, & millionaires on mushrooms
Episode 59: When scientists get mad online, for-profit cancer care, & the perils of naming a startup
Episode 58: Democratizing CRISPR, drugging the undruggable, and reading pharma's fine print
Episode 57: Trump’s drug pricing foot soldier, Gilead’s uncertain future, & transpacific angst
Episode 56: Cheaper insulin, the next Juul, and diagnosing disease with sound
Episode 55: The fate of Bristol-Myers-Celgene, the tragedy of SIDS, and health tech's challenges
Episode 54: Another big Alzheimer’s failure, postpartum progress, and Long Island shores
Episode 53: How startups stop, the new FDA boss, and Theranos on the big screen
Episode 52: Every conceivable angle of Scott Gottlieb's FDA resignation
Episode 51: CEOs at the Senate, merger mania, and sleuthing startups
Episode 50: A big scoop on opioid marketing
Episode 49: Painkiller racketeering, the limits of genetic tests, and pharma's day on the Hill
Episode 48: The AI hype machine, ketamine's future, and the rocky path ahead for NASH
Episode 47: A bad day for bold biotech, campaign 2020, and where do drugs come from?
Episode 46: Another Alzheimer's setback, crypto for biotech, and a blessing of unicorns
Episode 45: CRISPR upheaval, Celgene's chutzpah, and canine genomics
Episode 44: FDA furloughs, '80s pop radio, and video game therapeutics
Episode 43: A people's history of J.P. Morgan
Episode 42: Parsing Bristol-Myers-Celgene, grousing about JPM, and how to not be boring
Episode 41: Watson's latest stumble, a glimpse into the crystal ball, and revisiting Sarepta
Episode 40: Gilead’s new boss, the year that was, and the thing about DNA tests
Episode 39: Using the word 'cure,' an FDA loophole, & making biotech history
Episode 38: Your guide to the #CRISPRbabies controversy
Episode 37: The biggest-ever IPO, drug prices rising in tandem, and burner Twitter accounts
Episode 36: What the midterms mean, a golden age on hold, and the $4 million drug
Episode 35: Biotech's October slump, the precise cost of precision, and breaking postpartum silence
Episode 34: Pharma at the ballot box, the latest Alzheimer's argument, and a rare disease dilemma
Episode 33: Drug prices on TV, immortal blockbusters, and genetic privacy
Episode 32: Fake friends at the FDA, cancer counter-narratives, and biotech's bear turn
Episode 31: Nobel snubs, millenial founders, and a new kind of lightning round
Episode 30: A fish oil epiphany, VC monopolies and ketamine clinics
Episode 29: A Hong Kong heat-check, a $20 million wrist slap, and pharma's (other) diversity problem
Episode 28: Founders' funds, doctors' disclosures, and the subtle art of beeping
Episode 27: Live from Boston!
Episode 26: FDA shows its teeth, biotech fish oil might be pointless, & treating McCain's cancer
Episode 25: A genome-editing first, Trump on Wall Street, and biotech red flags
Episode 24: A lesson in startup jargon, pharma's bare Alzheimer's cupboard, and the cost of CAR-T
Episode 23: Congressional insider trading, PETA and fake meat, & doctors vs. fund managers
Episode 22: Biotech's battle for talent, Sanofi's second act, and climbing Mt. Everest
Episode 21 - A debatable Alzheimer's breakthrough, Gilead's golden age, and "robust" data
Episode 20 - CRISPR freakouts, drug prices meet elections, and a busy earnings season
Episode 19: Trump's telephonic prowess, Biogen's mysterious future, & the rise of 'hypelines'
Episode 18: Biotech's six-month review, how to become a day trader and soul-searching analysts
Episode 17: A friendly FDA, biosimilar awkwardness and how to sell drugs in China
Episode 16: Sarepta's big week, Theranos' legal woes and parsing AI hype
Episode 15: Problematic parties, Nitpicking NASH, and an opioid documentary from STAT
Episode 14: Twitter vitriol, biotech jargon, and the plight of the CEO
Episode 13: Spending millions on fatty liver disease. Overhyped cancer drugs. Who goes to BIO?
Episode 12: Ebola should worry you, again; 23andMe's World Cup whoops; Don't drink sunscreen
Episode 11: Inside the Theranos collapse, Valeant's latest legal lumps, and a few biotech hot takes
Episode #10: Cohen, Trump, Novartis, oh my; Spark + Amish; Genetic testing at your doc's office?
Episode #9 - Bill Gates on deadly flu, Chinese biotech bubbles, Golden State killer genetics
Episode #8 - Megamergers, migraines, and biotech's Four Horsemen
Episode #7 - Coke and Pepsi of lung cancer, a debatable drug price, and a cure for capitalism
Episode #6 - Biotech buyouts, CEO breakups, and The Rock does CRISPR
Episode #5 - The FDA's cold shoulder, the latest CAR-T contender, and BuzzFeed's scoop on Grindr
Episode #4 - Mr. Drug CEO doesn't go to DC, billionaires fighting drug prices, a biotech report card
Episode #3 - A gene therapy story, breaking down Incyte’s future, and was Gottlieb wrong to try?
Episode #2 - Theranos’s fate, biotech’s awkward SXSW, and a word on cow loogies
Episode #1 - Shkreli's sentence, biotech froth, and a blood party
Coming soon: "The Readout LOUD"